Other languages Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Delayed Nasdaq Other stock markets 17:57:32 29/04/2024 BST			5-day change	1st Jan Change
1.519 ^USD	+4.74%		+4.86%	-14.20%

04-09	Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	CI
03-20	Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	04-09
Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2	03-19
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-19
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	02-12
Sector Update: Health Care Stocks Mixed in Afternoon Trading	02-09
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	02-09
Corvus Pharmaceuticals Says Soquelitinib Received FDA Orphan Drug Designation	02-09
Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer	02-06
Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors	01-23
Corvus Pharmaceuticals, Inc. Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial	12-09
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07
Corvus Pharmaceuticals Says Preclinical Data Showed Soquelitinib Was Active in Six Inflammatory, Immune Disease Models	11-02
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases	11-01
Corvus Pharmaceuticals, Inc. Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma	07/09/23
Corvus Completes FDA Meeting on Plans to Launch Phase 3 Cancer Trial; Shares Jump After-Hours	06/09/23
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23
Corvus Pharmaceuticals, Inc. Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference	29/06/23
Corvus Pharmaceuticals, Inc. Presents New Cpi-818 Interim Data At the International Conference on Malignant Lymphoma	15/06/23
Corvus Pharmaceuticals Extends Gains in Premarket Thursday After Reporting 'Strong Progress' in Immune Diseases Treatment	18/05/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Other languages

Filters